What the FDA labels say about taking them together
Deflazacort and rifampin
Deflazacort's FDA label of November 13, 2025 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name deflazacort. The deflazacort label: “Moderate or Strong CYP3A4 Inducers Co-administration of deflazacort with rifampin, a strong CYP3A4 inducer, significantly decreased the exposure of 21-desDFZ.”
Check it at the source: the deflazacort FDA label on DailyMed (effective November 13, 2025, PTC Therapeutics, Inc.); the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.).
What does the deflazacort label say about rifampin?
Deflazacort label, drug interactionsModerate or Strong CYP3A4 Inducers Co-administration of deflazacort with rifampin, a strong CYP3A4 inducer, significantly decreased the exposure of 21-desDFZ.
Source: FDA drug label (EMFLAZA), PTC Therapeutics, Inc., effective November 13, 2025 (SPL set 31b347d2-f156-4055-9d8f-7cf0df420296), via openFDA; the full label on DailyMed
What does the rifampin label say about deflazacort?
Rifampin's label (effective February 11, 2026) does not name deflazacort in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Deflazacort | Rifampin | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.679 per capsule 300 mg capsule |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once